Clinical Research Sample Clauses
The Clinical Research clause defines the terms and conditions under which clinical studies or trials are conducted within the scope of an agreement. It typically outlines the responsibilities of the parties involved, such as the sponsor and the research institution, including compliance with ethical standards, regulatory requirements, and data management protocols. This clause ensures that all clinical research activities are performed in accordance with applicable laws and guidelines, thereby protecting the rights of participants and maintaining the integrity of the research process.
Clinical Research. These Clinical Terms apply to all contracts that involve clinical research. The Government shall have unlimited rights to all protocols, data generated from the execution of these protocols, and final reports, funded by the Government under this contract, as defined in Rights in Data Clause in FAR 52.227-14. The Government reserves the right to request that the Contractor provide any contract deliverable in a non-proprietary form, to ensure the Government has the ability to review and distribute the deliverables, as the Government deems necessary.
Clinical Research. The parties recognize the benefits of participation in clinical research projects. The Union will be notified prior to implementation of any clinical research that impacts working conditions of bargaining unit employees. Participation in research projects will be voluntary, consistent with staff rights/policy and the Department’s right to assign work. Employees will receive training and written instructions regarding the intent and requirements of the research project prior to implementation. Staff involved in clinical research may be recognized for their participation/contribution to the project by the annual performance evaluation and other means; for example, monetary awards, acknowledgment in papers.
Clinical Research. Preparation of the final clinical study report for L-FMAU-102 is ongoing and is expected to be complete in March 2004. • Study L-FMAU-102B will continue until the last patient completes the study (currently targeted for Nov. 23, 2003). The final database lock is scheduled for December 31, 2003. The final data from this study will be provided. • Study FTCB-204 will continue until the last patient completes the study (currently targeted for June 2004). The final database lock is scheduled for July 22, 2004. The final data from this study will be provided. • All activities for study CLV-202 are being terminated. • The regulatory process for study CLV-205 in Turkey is ongoing. The possibility to transfer this filing to Bukwang to be discussed.
Clinical Research. DISTRIBUTOR shall not engage in, support or contribute to any clinical research and/or studies of any of the Products without the prior written consent of OTI and OTI’s prior review and written approval of the protocol for such clinical research or study.
Clinical Research. Essential Elements:
Clinical Research. Patient-oriented research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient- oriented research may include: Mechanisms of human disease; Therapeutic interventions; Clinical trials; Development of new technologies. 1
Clinical Research. BSD may propose additional clinical research to support enhanced marketing claims for Products. BSD will work with BTI to make any study generally supportive of the efficacy of the technology. If BTI agrees with the study protocol, clinical expenses will be shared 50/50%. Ownership of the research will be shared.
Clinical Research. The Educational Institution will not permit dissemination or publication of any clinical research without prior consent of the Agency, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, student may participate in Clinical Research in accordance with the appropriate professional and legal standards (as per the Use and Disclosure of Research section of The Health Information and Protection Act) to further Students’ academic standard including uses in theses, case studies, Student discussions, papers, research work and other similar academic activities.
Clinical Research. 3.19 BSC shall present clinical information regarding BSC Surgical Mesh in a truthful, non-misleading manner and with a balanced presentation of risks in relation to benefits.
3.20 BSC shall not, when citing to any clinical study, clinical data, or preclinical data regarding Surgical Mesh, misrepresent the result or scope of the cited information.
3.21 BSC shall register all BSC-Sponsored studies regarding its BSC Surgical Mesh with ▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ as required by 42 CFR Part 11.
3.22 BSC shall, when submitting a study or clinical data regarding BSC Surgical Mesh for publication, disclose BSC’s role as a Sponsor and any potential conflict of interest with BSC of which BSC is aware for any author consistent with the disclosure requirements for International Committee of Medical Journal Editors (ICMJE).
3.23 In relation to BSC Surgical Mesh, BSC shall not, in Marketing Materials, use, rely on, or cite to any clinical study, clinical data or preclinical data where it had control or possession of underlying scientific materials, documents, or raw data on or after November 15, 2012 but does not retain the same for the three-year period following the last date such Marketing Materials are distributed by BSC. This prohibition will not apply if BSC has not retained such underlying scientific materials, documents, or raw data if (1) it was not permitted to retain the underlying scientific materials, documents, or raw data; or (2) the study/data was published in a peer-reviewed journal or has otherwise entered the public domain.
3.24 In relation to BSC Surgical Mesh, BSC shall not, in Marketing Materials, use, rely on, or cite to any clinical study, clinical data, preclinical data, research, or article, (1) for which BSC has not complied with the disclosure requirements in paragraph 3.22, unless BSC provides the disclosure detailed in paragraph 3.22 in the Marketing Material that uses, relies on, or cites such clinical study, clinical data, preclinical data, research, or article, (2) Sponsored by BSC for which the institution or investigator has not complied with the disclosure requirements set forth in paragraph 3.17, unless BSC provides the disclosure detailed in paragraph 3.17 in the Marketing Material that uses, relies on, or cites such clinical study, clinical data, preclinical data, research, or article, or (3) Supported by BSC for which any author/consultant/investigator has not complied with the disclosure requirements set forth in paragraphs 3.16 or 3.18,...
Clinical Research. Except as otherwise provided in the agreement effective November 27, 1991 by and between SPARTA and CRL, to the extent requested by SPARTA and to the extent available by RTP and its affiliates, Cato Research Ltd. ("CRL") and Cato Pharma Canada, Ltd., RTP will make available its staff or that of said affiliates, to conduct ongoing clinical research activities related to the Applications being developed by SPARTA as requested by SPARTA and at SPARTA's expense, as mutually agreed by the applicable parties.